Abbott has seen "no signals of lung cancer" in patient trials of its experimental inhaled insulin, a company spokesman said Thursday.
Abbott's disclosure comes a day after Pfizer Inc. (PFE) warned that a small number of users of its inhaled insulin, Exubera, developed lung cancer, though it wasn't able to determine whether Exubera was the cause. Pfizer decided last year to stop marketing Exubera due to disappointing market performance since it was approved in 2006; the company is working with doctors to switch patients from Exubera to other therapies.
Abbott inherited an early-stage inhaled-insulin development program when it acquired Kos Pharmaceutical in 2006. The product is in the middle stage, or Phase 2, of human testing.
"We've seen no signals of lung cancer in our trials," Abbott spokesman Kurt Ebenhoch told Dow Jones Newswires Thursday.
More
Insider's view: Well, that's all ok then.
Must just be an Exubera problem!
So.....
Volunteers for the large Phase 3 studies please form an orderly line!!
No comments:
Post a Comment